|
|
Evolutions in the Management of Duchenne Muscular Dystrophy (DMD): Treatment Implications for the Present and Future
Target Audience
This educational activity is intended for healthcare professionals involved in the management of patients with Duchenne Muscular Dystrophy (DMD), including neurologists, neuromuscular specialists, and other members of the healthcare team who care for patients with DMD.
Program Overview
Duchenne muscular dystrophy (DMD) impacts 1 in every 3,500 male births globally, and its progression is both relentless and fatal. However, the rapid advancement in DMD therapies brings hope... |
|
|
Updates on the Evolving Role of Multidisciplinary Care Teams for the Management of Patients with Duchenne Muscular Dystrophy
Target Audience
These educational activities are designed for neurologists, pediatric neurologists, global pharmacists, specialty nurses, genetic counselors, medical geneticists, and other physicians involved in multidisciplinary care teams for DMD management.
Program Overview
This enduring activity focuses on improving the care of patients with Duchenne muscular dystrophy (DMD) with regard to effective diagnosis, referral, and treatment. Additionally, the faculty will aim to present stan... |
|
|
Improving the Management of Patients With Duchenne Muscular Dystrophy: Emerging Evidence and Treatment Strategies
Target Audience
This activity is designed to meet the educational needs of health care professionals involved in the management of patients with Duchenne muscular dystrophy (DMD), including neurologists and other neuromuscular specialists, with a portion targeting pediatricians.
Program Overview
Expand your knowledge of DMD by exploring real patient case reviews! Gain a deeper understanding of dystrophin’s role in disease progression, explore the latest clinical trial results across tre... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Peripheral Nerve Ultrasound " Blended Course
The Blended Peripheral Nerve Ultrasound Course is designed to provide practical training for mastering peripheral nerve ultrasound and neuromuscular assessment. The Blended Education format provides flexibility while providing time and cost savings.
Begin with the self-paced online course: Taught by leading peripheral nerve and musculoskeletal ultrasound experts, the online course incorporates a comprehensive review of the sonographic anatomy of upper and lower limb peripheral nerves and as... |
|
|
FcRn and Myasthenia Gravis
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate.
Program Overview
This 30-minute CME program discusses how the FcRn system can impact myasthenia gravis and how FcRn antagonists can be used to treat this rare condition.
Learning Objectives
After part... |
|
|
Cleveland Clinic 15th Annual Neurology Update
The Cleveland Clinic 15th Annual Neurology Update addresses the latest clinically focused trends and most pertinent topics in the specialty. A faculty of 17 acclaimed experts provide the newest information regarding the diagnosis, medication and therapy for a wide range of neurologic conditions. Worth 15.5 AMA PRA Category I Credits™, this wealth of information will widen healthcare practitioners’ neurologic knowledge base and enhance patient care.
Topics include: Dementia, headache, ... |
|